Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 12
Submit an article Journal homepage
250
Views
10
CrossRef citations to date
0
Altmetric
Original Article: Clinical

The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma

Naoto TomitaDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan; Correspondence[email protected]
,
Taisei SuzukiDepartment of Hematology, Yokosuka City Hospital, Yokosuka, Japan;
,
Kazuho MiyashitaDepartment of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan;
,
Wataru YamamotoDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan;
,
Kenji MotohashiDepartment of Hematology, Yokohama City University Medical Center, Yokohama, Japan;
,
Takayoshi TachibanaDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan;
,
Hirotaka TakasakiDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan;
,
Rika KawasakiDepartment of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan;
,
Maki HagiharaDepartment of Hematology, Yokohama City University Medical Center, Yokohama, Japan;
,
Chizuko HashimotoDepartment of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan;
,
Sachiya TakemuraDepartment of Internal Medicine, Yokohama Ekisaikai Hospital, Yokohama, Japan;
,
Hideyuki KoharazawaDepartment of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan;
,
Etsuko YamazakiDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan;
,
Jun TaguchiDepartment of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan;
,
Katsumichi FujimakiDepartment of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan;
,
Hiroyuki FujitaDepartment of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan;
,
Rika SakaiDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan;
,
Shin FujisawaDepartment of Hematology, Yokohama City University Medical Center, Yokohama, Japan;
,
Shigeki MotomuraDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan;
,
Keisuke KawamotoDepartment of Hematology, Endocrinology, and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan
,
Hirohito SoneDepartment of Hematology, Endocrinology, and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan
&
Jun TakizawaDepartment of Hematology, Endocrinology, and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan
 show all
Pages 2763-2770 | Received 10 Feb 2016, Accepted 24 May 2016, Published online: 20 Jun 2016

References

  • A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–994.
  • Dajczman E, Kasymjanova G, Kreisman H, et al. Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol. 2008;3:1133–1136.
  • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
  • Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006.
  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
  • Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126.
  • Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–1022.
  • Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–1861.
  • Yoshida N, Oda M, Kuroda Y, et al. Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One. 2013;8:e78730.
  • Paietta E, Nelson DL, Andersen J, et al. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells. Med Oncol. 1995;12:121–124.
  • Lemmer B, Schwuléra U, Thrun A, et al. Circadian rhythm of soluble interleukin-2 receptor in healthy individuals. Eur Cytokine Netw. 1992;3:335–336.
  • Tomita N, Sakai R, Fujisawa S, et al. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma. Cancer Sci. 2012;103:1518–1523.
  • Ennishi D, Yokoyama M, Terui Y, et al. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol. 2009;20:526–533.
  • Tomita N, Kodama F, Kanamori H, et al. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer. 2002;95:576–580.
  • Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC Press; 2001.
  • Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
  • Tomita N, Takasaki H, Miyashita K, et al. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. Br J Haematol. 2013;161:383–388.
  • Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–26.
  • Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258–2263.
  • Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;118:4166–4172.
  • Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–842.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.